TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients

(2015) D. Planchard et al.   ANNALS OF ONCOLOGY

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

(2015) C. A. Eberlein et al.   CANCER RESEARCH

Structure-based hybridization, synthesis and biological evaluation of novel tetracyclic heterocyclic azathioxanthone analogues as potential antitumor agents

(2015) Tsung-Chih Chen et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib forEGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

(2015) Melissa L. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

(2015) Chee-Seng Tan et al.   LANCET ONCOLOGY

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability

(2015) D-W Wu et al.   ONCOGENE

EGFR-activated Src family kinases maintain GAB1-SHP2 complexes distal from EGFR

(2015) Christopher M. Furcht et al.   Science Signaling

EGFR-activated Src family kinases maintain GAB1-SHP2 complexes distal from EGFR

(2015) Christopher M. Furcht et al.   Science Signaling

Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy

(2015) D. A. Proia et al.   Cancer Immunology Research

EGFR-mutated lung cancer: a paradigm of molecular oncology

(2015)   Oncotarget

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation

(2014) Junya Nakade et al.   Journal of Thoracic Oncology

Combining Onartuzumab with Erlotinib Inhibits Growth of Non-Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression

(2014) Y. Sano et al.   MOLECULAR CANCER THERAPEUTICS

Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth

(2014) Sung Keun Jung et al.   MOLECULAR CARCINOGENESIS

FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction

(2014) D-W Wu et al.   ONCOGENE

Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors

(2014) Bálint Szokol et al.   ACS Medicinal Chemistry Letters

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

(2013) N. Miyajima et al.   CANCER RESEARCH

MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation

(2013) J. K. Rho et al.   CANCER RESEARCH

Inhibition of HSP90 molecular chaperones: moving into the clinic

(2013) Rocio Garcia-Carbonero et al.   LANCET ONCOLOGY

The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non-Small Cell Lung Cancer Growth

(2013) E. B. Garon et al.   MOLECULAR CANCER THERAPEUTICS

Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression

(2013) D-W Wu et al.   ONCOGENE

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors

(2013) Shigeki Nanjo et al.   PLoS One

Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer

(2012) Shinji Takeuchi et al.   AMERICAN JOURNAL OF PATHOLOGY

Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

(2012) L. Xu et al.   CANCER RESEARCH

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

(2012) L. Neckers et al.   CLINICAL CANCER RESEARCH

Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis

(2012) Hitomi Koizumi et al.   Journal of Thoracic Oncology

Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

(2012) T. Nakagawa et al.   MOLECULAR CANCER THERAPEUTICS

MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib

(2012) Ming-Hung Huang et al.   Molecular Oncology

Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers

(2011) Komal Jhaveri et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition

(2011) T. Bachleitner-Hofmann et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

(2011) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor

(2011) Naruyuki Kobayashi et al.   LUNG CANCER

EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers

(2011) Michela Garofalo et al.   NATURE MEDICINE

Personalized medicine in lung cancer: what we need to know

(2011) Tony S. K. Mok   Nature Reviews Clinical Oncology

HGF-independent potentiation of EGFR action by c-Met

(2011) A M Dulak et al.   ONCOGENE

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

(2010) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Taming Glioblastoma by Targeting Angiogenesis: 3 Years Later

(2010) Eric T. Wong et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer

(2009) R. Bao et al.   MOLECULAR CANCER THERAPEUTICS

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer

(2008) Z Tang et al.   BRITISH JOURNAL OF CANCER

Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

(2008) T. Shimamura et al.   CANCER RESEARCH